Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Cash and Equivalents of $89.13 million for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $89.13M | +16.9% |
| 2024 | $76.25M | -13.6% |
| 2023 | $88.20M | -36.7% |
| 2022 | $139.26M | -31.4% |
| 2021 | $203.13M | +59.4% |
| 2020 | $127.44M | +57.5% |
| 2019 | $80.93M | +14.8% |
| 2018 | $70.50M | -31.4% |
| 2017 | $102.72M | -36.1% |
| 2016 | $160.75M | +124.0% |
| 2015 | $71.76M | +411.5% |
| 2014 | $14.03M | -80.4% |
| 2013 | $71.56M | -21.6% |
| 2012 | $91.30M | -22.4% |
| 2011 | $117.66M | +51.1% |
| 2010 | $77.88M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $92.71M | -63.5% | +14.6% |
| June 30, 2025 | $80.87M | -4.3% | +2.4% |
| March 31, 2025 | $78.96M | -33.5% | +3.6% |
| December 31, 2024 | $76.25M | -13.6% | -69.9% |
| September 30, 2024 | $253.73M | +294.4% | +200.2% |
| June 30, 2024 | $84.52M | -0.3% | -28.8% |
| March 31, 2024 | $118.76M | +14.0% | +34.6% |
| December 31, 2023 | $88.20M | -36.7% | +37.1% |
- AGIOS PHARMACEUTICALS, INC. showed an increase of +16.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, AGIOS PHARMACEUTICALS, INC.’s cash and equivalents has grown by 14.4% (from $77.88 million to $89.13 million).
- The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: